...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Gilead's GS-5829 flops in mCRPC

NBB - I would think Gilead will take a break for a spell, change some personnel and then rethink their path going forward. If this is the drug I think it is then Gilead has just figured out that they have paid $21 billion dollars on a glug glug machine.

tada

3
Jul 20, 2022 09:26AM
Share
New Message
Please login to post a reply